Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/234528 |
Resumo: | Background: Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, life-limiting lysosomal storage disease caused by defcient iduronate-2-sulfatase activity. Enzyme replacement therapy (ERT) with intravenous (IV) idursulfase can stabilize or improve many somatic manifestations, but there remains a need for further analysis of long-term treatment outcomes. Using data from patients with MPS II enrolled in the Hunter Outcome Survey (HOS), mixed modeling was performed to evaluate and predict the efects of IV idursulfase treatment on selected clinical parameters for up to 8 years following treatment start. The modeling population comprised male patients followed prospectively in HOS who had received IV idursulfase for at least 5 years and who had data available for two or more time points (at least one post-ERT). Age at ERT start and time since ERT start were included as covariates. Results: In total, 481 patients were eligible for inclusion in at least one model. At 8 years post-ERT start, improvement from baseline was predicted for each age group (<18 months, 18 months to<5 years and≥5 years at treatment start) in the following parameters: mean urinary glycosaminoglycan levels (percentage changes of>–75% in each group), mean left ventricular mass index (decreases of~1 g/m2 ) and mean palpable liver size (decreases of>2 cm). Improvements in mean 6-min walk test distance (increase of>50 m) and stabilization in percent predicted forced vital capacity and forced expiratory volume in 1 s (decreases of~4 and~9 percentage points, respectively) at 8 years post-ERT start were predicted for patients aged≥5 years at ERT start (these assessments are unsuitable for patients aged<5 years). Predicted changes over time were similar across the three age groups; however, overall outcomes were most favorable in children aged<18 months at ERT start. Conclusions: These fndings suggest that the previously reported positive efects of IV idursulfase on the somatic manifestations of MPS II are predicted to be maintained for at least 8 years following ERT initiation and highlight the value of statistical modeling to predict long-term treatment outcomes in patients with rare diseases. |
id |
UFRGS-2_184e5dc0018c9c74aa88467056627307 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/234528 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Muenzer, JosephBotha, JacoHarmatz, PaulGiugliani, RobertoKampmann, ChristophBurton, Barbara K.2022-01-27T04:33:41Z20211750-1172http://hdl.handle.net/10183/234528001135869Background: Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, life-limiting lysosomal storage disease caused by defcient iduronate-2-sulfatase activity. Enzyme replacement therapy (ERT) with intravenous (IV) idursulfase can stabilize or improve many somatic manifestations, but there remains a need for further analysis of long-term treatment outcomes. Using data from patients with MPS II enrolled in the Hunter Outcome Survey (HOS), mixed modeling was performed to evaluate and predict the efects of IV idursulfase treatment on selected clinical parameters for up to 8 years following treatment start. The modeling population comprised male patients followed prospectively in HOS who had received IV idursulfase for at least 5 years and who had data available for two or more time points (at least one post-ERT). Age at ERT start and time since ERT start were included as covariates. Results: In total, 481 patients were eligible for inclusion in at least one model. At 8 years post-ERT start, improvement from baseline was predicted for each age group (<18 months, 18 months to<5 years and≥5 years at treatment start) in the following parameters: mean urinary glycosaminoglycan levels (percentage changes of>–75% in each group), mean left ventricular mass index (decreases of~1 g/m2 ) and mean palpable liver size (decreases of>2 cm). Improvements in mean 6-min walk test distance (increase of>50 m) and stabilization in percent predicted forced vital capacity and forced expiratory volume in 1 s (decreases of~4 and~9 percentage points, respectively) at 8 years post-ERT start were predicted for patients aged≥5 years at ERT start (these assessments are unsuitable for patients aged<5 years). Predicted changes over time were similar across the three age groups; however, overall outcomes were most favorable in children aged<18 months at ERT start. Conclusions: These fndings suggest that the previously reported positive efects of IV idursulfase on the somatic manifestations of MPS II are predicted to be maintained for at least 8 years following ERT initiation and highlight the value of statistical modeling to predict long-term treatment outcomes in patients with rare diseases.application/pdfengOrphanet journal of rare diseases. [London]. Vol. 16 (2021), 456, 14 p.Mucopolissacaridose IIDoenças por armazenamento dos lisossomosModelos estatísticosPrognósticoTratamento farmacológicoTerapia de reposição de enzimasMucopolysaccharidosis IIMPS IIHunter syndromeLysosomal storage diseaseStatistical modelingDisease registryIdursulfaseEnzyme replacement therapyEvaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS)Estrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001135869.pdf.txt001135869.pdf.txtExtracted Texttext/plain66610http://www.lume.ufrgs.br/bitstream/10183/234528/2/001135869.pdf.txt120067f54858093e16f193387e22d1ffMD52ORIGINAL001135869.pdfTexto completo (inglês)application/pdf2321130http://www.lume.ufrgs.br/bitstream/10183/234528/1/001135869.pdf5ec81f17cbf9a8d3d1b9330c78b37bd6MD5110183/2345282023-06-24 03:37:57.467168oai:www.lume.ufrgs.br:10183/234528Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-24T06:37:57Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
title |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
spellingShingle |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) Muenzer, Joseph Mucopolissacaridose II Doenças por armazenamento dos lisossomos Modelos estatísticos Prognóstico Tratamento farmacológico Terapia de reposição de enzimas Mucopolysaccharidosis II MPS II Hunter syndrome Lysosomal storage disease Statistical modeling Disease registry Idursulfase Enzyme replacement therapy |
title_short |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
title_full |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
title_fullStr |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
title_full_unstemmed |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
title_sort |
Evaluation of the long-term treatment efects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling : data from the Hunter Outcome Survey (HOS) |
author |
Muenzer, Joseph |
author_facet |
Muenzer, Joseph Botha, Jaco Harmatz, Paul Giugliani, Roberto Kampmann, Christoph Burton, Barbara K. |
author_role |
author |
author2 |
Botha, Jaco Harmatz, Paul Giugliani, Roberto Kampmann, Christoph Burton, Barbara K. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Muenzer, Joseph Botha, Jaco Harmatz, Paul Giugliani, Roberto Kampmann, Christoph Burton, Barbara K. |
dc.subject.por.fl_str_mv |
Mucopolissacaridose II Doenças por armazenamento dos lisossomos Modelos estatísticos Prognóstico Tratamento farmacológico Terapia de reposição de enzimas |
topic |
Mucopolissacaridose II Doenças por armazenamento dos lisossomos Modelos estatísticos Prognóstico Tratamento farmacológico Terapia de reposição de enzimas Mucopolysaccharidosis II MPS II Hunter syndrome Lysosomal storage disease Statistical modeling Disease registry Idursulfase Enzyme replacement therapy |
dc.subject.eng.fl_str_mv |
Mucopolysaccharidosis II MPS II Hunter syndrome Lysosomal storage disease Statistical modeling Disease registry Idursulfase Enzyme replacement therapy |
description |
Background: Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, life-limiting lysosomal storage disease caused by defcient iduronate-2-sulfatase activity. Enzyme replacement therapy (ERT) with intravenous (IV) idursulfase can stabilize or improve many somatic manifestations, but there remains a need for further analysis of long-term treatment outcomes. Using data from patients with MPS II enrolled in the Hunter Outcome Survey (HOS), mixed modeling was performed to evaluate and predict the efects of IV idursulfase treatment on selected clinical parameters for up to 8 years following treatment start. The modeling population comprised male patients followed prospectively in HOS who had received IV idursulfase for at least 5 years and who had data available for two or more time points (at least one post-ERT). Age at ERT start and time since ERT start were included as covariates. Results: In total, 481 patients were eligible for inclusion in at least one model. At 8 years post-ERT start, improvement from baseline was predicted for each age group (<18 months, 18 months to<5 years and≥5 years at treatment start) in the following parameters: mean urinary glycosaminoglycan levels (percentage changes of>–75% in each group), mean left ventricular mass index (decreases of~1 g/m2 ) and mean palpable liver size (decreases of>2 cm). Improvements in mean 6-min walk test distance (increase of>50 m) and stabilization in percent predicted forced vital capacity and forced expiratory volume in 1 s (decreases of~4 and~9 percentage points, respectively) at 8 years post-ERT start were predicted for patients aged≥5 years at ERT start (these assessments are unsuitable for patients aged<5 years). Predicted changes over time were similar across the three age groups; however, overall outcomes were most favorable in children aged<18 months at ERT start. Conclusions: These fndings suggest that the previously reported positive efects of IV idursulfase on the somatic manifestations of MPS II are predicted to be maintained for at least 8 years following ERT initiation and highlight the value of statistical modeling to predict long-term treatment outcomes in patients with rare diseases. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021 |
dc.date.accessioned.fl_str_mv |
2022-01-27T04:33:41Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/234528 |
dc.identifier.issn.pt_BR.fl_str_mv |
1750-1172 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001135869 |
identifier_str_mv |
1750-1172 001135869 |
url |
http://hdl.handle.net/10183/234528 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Orphanet journal of rare diseases. [London]. Vol. 16 (2021), 456, 14 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/234528/2/001135869.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/234528/1/001135869.pdf |
bitstream.checksum.fl_str_mv |
120067f54858093e16f193387e22d1ff 5ec81f17cbf9a8d3d1b9330c78b37bd6 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1798487506970214400 |